news
Zealand Pharma's amylin drug shows 8-11% weight loss, fewer side effects
Zealand Pharma and Roche's new amylin-based obesity drug, petrelintide, hit Phase II targets. The drug delivered 8–11% weight loss in trials and reportedly comes with fewer of the tough gastrointestinal side effects common in other incretin drugs. This suggests a potentially smoother path to body composition changes for some.
Zealand Pharma and Roche's new amylin-based obesity drug, petrelintide, hit Phase II targets. The drug delivered 8–11% weight loss in trials and reportedly comes with fewer of the tough gastrointestinal side effects common in other incretin drugs. This suggests a potentially smoother path to body composition changes for some.
The architecture take
I keep hearing that GLP-1 drugs are a magic bullet, but the nausea and gut issues sideline a lot of people. This new drug, petrelintide, uses amylin, a hormone co-secreted with insulin that helps control blood sugar and satiety. The 8-11% average weight loss is on par with some of the earlier GLP-1 results, but the real play here is the promise of fewer side effects. If it can deliver comparable results with a more tolerable profile, it's a game-changer for adherence. People won't stop taking something if it doesn't make them feel sick all the time. I'll be watching how this impacts the mental load of managing chronic conditions, which often goes unmeasured in these trials. Less gut distress means more regulated daily state, fewer cortisol spikes from discomfort. That's a win.